HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells.

AbstractBACKGROUND:
Atrial natriuretic peptide (ANP) and long acting natriuretic peptide (LANP) have anticancer effects in human prostate adenocarcinomas.
MATERIALS AND METHODS:
ANP, LANP and cyclic GMP's effects on extracellular signal-regulated kinase (ERK) 1/2 kinase were examined in human prostate adenocarcinoma cells.
RESULTS:
ANP and LANP decreased the activation of ERK 1/2 over a concentration range of 0.01 microM to 10 microM. ANP and LANP's maximal inhibition of the phosphorylation of ERK 1/2 kinase were 94% and 88% (p < 0.0001), respectively. ANP had significant effects within five min at its 10 microM concentration. The inhibition of ERK 1/2 lasted for at least two h, where it was maximal, secondary to both peptides. Their ability to inhibit ERK 1/2 was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited ERK 1/2 phosphorylation.
CONCLUSION:
ANP and LANP both inhibit ERK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action.
AuthorsYing Sun, Ehrentraud J Eichelbaum, Hai Wang, David L Vesely
JournalAnticancer research (Anticancer Res) 2006 Nov-Dec Vol. 26 Issue 6B Pg. 4143-8 ISSN: 0250-7005 [Print] Greece
PMID17201125 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Enzyme Inhibitors
  • Atrial Natriuretic Factor
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Cyclic GMP
Topics
  • Atrial Natriuretic Factor (pharmacology)
  • Cell Line, Tumor
  • Cyclic GMP (immunology)
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Male
  • Mitogen-Activated Protein Kinase 1 (antagonists & inhibitors)
  • Mitogen-Activated Protein Kinase 3 (antagonists & inhibitors)
  • Prostatic Neoplasms (enzymology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: